HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 23, No 06, June 2019 – Clinical trials — What's in a name?       » Study reveals mechanism behind ginger's warming effect on body       » China proposes major changes to pharmaceutical regulations       » Six plants native to Southeast Asia are promising cancer warriors       » Cancer cells are addicted to methionine       » World's first molecular swing      
EYE ON CHINA
Merck collaborates with GenScript to accelerate cell and gene therapy industrialisation in China
Collaboration to build global-standard platform for plasmid and virus manufacturing in China

A strategic alliance between pharma giant, Merck and Chinese biotech company, GenScript, aim to accelerate the industrialisation and commercialisation of cell and gene therapy in China.

The manufacturing of high-quality plasmid and viral vectors is one of the most critical components in the commercialisation of cell and gene therapy.

Merck is among only a few manufacturers that have an industrialised process to make viral vectors.

To create personalised therapy products, genes are delivered into immune cells using viral vectors.

A confluence of demand, growth and subsequent need to scale the cell and gene therapy market in China is an important driver for Merck to deliver its expertise to this region. According to clinicaltrials.gov, China is the world-leader in terms of where gene-modified cell therapy clinical trials are conducted.

Today, more than 130 companies in China are developing cell and gene therapies ranging from chimeric antigen receptor T cell therapy (CAR-T) / T cell receptor therapy (TCR-T) and adeno-associated virus (AAV) to oncolytic virus.

Moreover, 28 cell and gene therapy Investigational New Drug applications were submitted in China between December 2017 to December 2018 with more than a third already approved for clinical trials.

Merck plans to provide a complete set of process products, services and staff training to support GenScript in creating a global-standard platform of plasmid and virus manufacturing service in the country.

Source: Merck

Click here for the complete issue.

NEWS CRUNCH  
news Which country has the worst sleepers
news Asia is the fastest growing region for nutraceuticals
news 2018 Nobel Prize in Physiology or Medicine winners
news Vitafoods Asia expands by 40 per cent in 2018
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  

APBN Editorial Calendar 2019
January:
Taiwan Medical tourism
February:
Marijuana as medicine — Legal marijuana will open up scientific research
March:
Driven by curiosity
April:
Career developments for researchers
May:
What's cracking — Antibodies in ostrich eggs
June:
Clinical trials — What's in a name?
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2019 World Scientific Publishing Co Pte Ltd  •  Privacy Policy